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Summary The coordinate expression of the nuclear p53 protein, cytoplasmic intermediate filament vimentin
(VIM) and membrane epidermal growth factor receptor (EGF-R) was significantly associated with oestrogen
receptor immunocytochemical nuclear stain (ER-ICA) negative breast carcinomas. Twenty-three (51.1%), 26
(57.8%) and 27 (60%) of 45 ER-ICA -ve cancers were respectively p53 +ve, VIM +ve and EGF-R +ve;
whereas of 151 ER-ICA +ve tumours 8 (5.3%) were p53 +ve (P<0.0001), 23 (15.2%) VIM +ve (P<0.001)
and 40 (26.5%) EGF-R +ve P<0.001). Thirty-six of 45 (80%) ER-ICA -ve carcinomas were positive for at
least one of the markers versus 55/151 (36.4%) ER-ICA +ve cases (X2=28.92, P<0.001). A prevalence of
high grade carcinomas was found among p53 +ve, VIM +ve cases; the latter subset of tumours also had a
larger mean diameter. These results suggest that ER -ve breast carcinoma cells display a coordinate
expression of cell cycle-related proteins and marked changes of both the cytoskeleton and the membrane
receptor repertoire.
The presence of receptors for the steroid hormone oestrogen
(ER) divides breast cancer into two groups with different
biological and clinical characteristics; the ER +ve subset is
associated with a longer relapse-free survival (McGuire et
al., 1986) when stage II patients or postmenopausal women
are considered. Other factors such as progesterone receptors
(McGuire et al., 1986), thymidine labelling index (Silvestrini
et al., 1984) and S-phase fraction (McGuire & Dressler
1985), may predict disease-free survival.
Recently the epidermal growth factor receptor (EGF-R)
was shown to be positively associated with high grade,
ER -ve carcinomas and has been suggested as an additional
cell marker to further segregate prognostically relevant
breast cancer subsets (Sainsbury et al., 1987).
We extended the search for biologically relevant markers
in breast cancer and focused on two unrelated cell
components of putative interest, the p53 protein and the
cytoskeletal protein vimentin, after an extensive screening of
several well characterized and new monoclonal antibodies.
p53 is a transformation-associated protein which has been
included in the group of nuclear oncogenes because of its
ability to immortalize normal cells and transform them in
cooperation with a mutated oncogene (Eliyahu et al., 1984).
Vimentin, a class III intermediate filament (IF), is distributed
on all mesenchymal cells and is coexpressed with other
intermediate filaments on an increasing variety of epithelial
tumours (Gould, 1985). Its presence on breast cancer cells
was first described in pleural malignant effusions (Ramaekers
et al., 1983).
The function of vimentin is still unknown, but according
to tentative explanation (Traub, 1985), vimentin is a nucleic
acid-binding protein, regulated through a Ca+ + dependent
proteinase, which is stored as polymerized filaments in the
cytoplasm. The DNA-binding sequences of vimentin are
analogous to the homologous region of the steroid hormone
receptors (Traub, 1985).
In this study we show that p53, vimentin and EGF-R are
expressed in Er -ve breast cancer cases and that they
correlate positively with each other.
Materials and methods
Antibodies
PAb421 mouse anti-p53 monoclonal antibody (MAb) was
kindly supplied as supernatant by Dr L. Crawford (Imperial
Cancer Research Fund, London, UK). Anti-epidermal
growth factor receptor RI (M. Waterfield, ICRF, London,
UK), anti-vimentin monoclonal (Amersham, Amersham,
UK) and polyclonal antibodies (Euro BT, Roma, Italy) were
also used. Both anti-vimentin antibodies gave identical
reactivity on frozen sections of several types of normal and
neoplastic tissues. They did not react with simple and
stratified epithelia, skeletal muscle, most smooth muscle cells,
parasympathetic ganglia and several tumour samples
reported in the literature as negative for vimentin. A third
anti-vimentin antibody (17fG3 from Ortho Diagnostic
Systems, Raritan, NJ) crossreactive with GFAP, gave
identical but weaker staining on the breast carcinomas
tested, and was therefore excluded. The rabbit anti-vimentin
antibody was used for the double labelling technique and for
revealing the presence of vimentin on formalin-fixed,
paraffin-embedded specimens stained for iconographic
purposes. Breast cancer sections were stained for cyto-
keratins 8, 18 and 19 (MAb K4.62 from Bio-Yeda, Rehovot,
Israel, and MAb UCD/PR 10.11 from Prof. R. Cardiff, UC
Davis Medical Center, California, USA) with and without
simultaneous vimentin staining. The rat anti-nuclear
oestrogen receptor MAb (ER-ICA) was purchased from
Abbott (Wiesbaden, FRG). Mouse MAbs directed against
sheep red blood cells (Seralab, Crawley Down, UK) were
used as negative controls.
All primary antibodies were used at saturating
concentration after careful titration on appropriate targets
and counterlabelled by indirect immunoalkaline phosphatase
or immunoperoxidase methods as previously described
(Cattoretti et al., 1988). Double immunohistochemical
staining was performed by first staining the nuclei for ER-
ICA with the immunoperoxidase stain and then the
cytoplasm for vimentin with Fast Blue BB immunoalkaline
phosphatase stain.. Double immunofluorescence was
performed by incubating the slides with both the mouse anti-
keratin and the rabbit anti-vimentin antibodies, and then by
counterstaining with both the FITC anti-rabbit and the
TRITC anti-mouse goat antibodies. The slides were then
photographed with a Leitz epifluorescence microscope using
Ilford HP4 B&W film.
Patients and tissues
Fresh biopsy specimens from the operating theatre were
snap-frozen in liquid nitrogen-cold isopentane (BDH, Poole,
UK). A parallel sample was processed with routine,
techniques for morphological evaluation on paraffin sections.
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One hundred and niney-six primary breast carcinomas
from 194 female and 2 male patients (aged 23-86 years;
mean 53.04 +0.797 s.e.) were collected: diameters ranged
from 0.4 to 20cm (median 1.9, mean 2.36+0.15 s.e.). One
hundred and six were free of lymph-node metastasis, 33 had
up to two positive nodes and 57 had three or more positive
lymph nodes.
Immunohistochemistry
Immunohistochemical evaluation was performed on 4jum
thick frozen sections placed on clean glass slides and fixed in
acetone or 10% buffered formaline (ER-ICA).
EGF-R and vimentin were considered positive when 10%
or more of the tumour cells were stained. P53 and ER-ICA
staining were considered positive when neoplastic cells
exhibited unambiguous nuclear staining irrespective of the
percentage of the positive cells. PAb421 antibody weakly
cross-reacts with cytoplasmic cytokeratins and therefore
nuclear staining only was evaluated (Cattoretti et al., 1988).
Oestrogen (ER) and progesterone (PgR) receptors were
measured simultaneously by a dual label dextran-coated
charcoal (DCC) adsorption assay, previously described
(DiFronzo et al., 1986), by a single laboratory (Division of
Experimental Oncology 'C', INT, Milano) on 132 unselected
samples from 196 cases. Histologic typing was performed
according to the guidelines recommended by the WHO and
the histologic grading of the tumours was evaluated
according to Bloom and Richardson (1957).
Results
The analysis of 196 primary breast cancer specimens for p53,
vimentin (VIM) and EGF-R showed that 15.8%, 25% and
34.2% respectively were positive with the appropriate
antibody on tumour cells (Table I).
p53 (MAb PAb421) stained the nucleus of neoplastic
(Figure la) but not normal epithelial cells (2 fibroadenomas,
2 lactating breast specimens, 6 mammary dysplasias and
normal residual tissue surrounding breast carcinomas).
Positive tumours were stained uniformly throughout the
sections.
VIM + ve breast cancer cells had cytoplasmic fibrillary
streaks of variable intensity (Figure lb). The staining was
irregulary distributed on each specimen. Double staining for
VIM and keratin (Figure 2) and for VIM and ER (Figure 3)
confirmed that the positive cells were in fact neoplastic
epithelium. Connective tissue cells and lymphocytes were
*positive for vimentin in all specimens tested.
EGF-R was revealed by an exclusive membrane positivity
(Figure 1c) and was homogeneously expressed on the totality
of the tumour cells in most specimens.
The immunohistochemical ER staining (ER-ICA) was
found on the nucleus of neoplastic cells and also in residual
normal breast ductal cells; tumour heterogeneity was
observed even though clearly negative and positive cases
could be identified (see also DiFronzo et al., 1986).
p53, VIM and EGF-R were distributed preferentially on
ER-ICA -ve carcinomas (Table I).
As expected, p53, VIM and EGF-R reactivity largely (but
not completely) overlapped on ER -ve specimens: 40/91
tumours found positive with one marker displayed an
additional one or two antigens (Table II) and 36/45 (80%)
ER-ICA -ve cases were positive for at least one marker
versus 55/151 (36.4%) ER-ICA +ve ones (X2 =28.92,
P<0.001).
Any combination of p53, VIM and EGF-R was signifi-
cantly associated with ER-ICA -ve tumours (not shown),
although the addition of p53 to VIM or EGF-R or the
combination of both greatly reduced the absolute figures for
ER-ICA coespression (Table II).
p53 alone or in combination seemed to be the major
source of this effect, probably because it was found to be
more restricted to the ER -ve tumours. Therefore, its
contribution to the relationship of VIM and EGF-R with
ER-ICA was assayed by evaluating the tumour panel
without the p53 +ve cases; after removing the effect of p53,
VIM and EGF-R still stained significantly more ER-ICA
-ve carcinomas or tumours with less than 50% positive
nuclei (Table III).
In 9 cases (4.59%) none of the determinants was
expressed.
Oestrogen and/or progesterone receptors, determined bio-
chemically, were significantly lower on p53 +ve (ER and
PgR) and EGF-R +ve (PgR) carcinomas (Table IV).
p53, VIM and EGF-R +ve carcinomas were evaluated for
the known parameters used to stage breast cancer; lymph
node status was unrelated to the presence of the above cited
markers, irrespective whether negative vs positive or 0-3
positive vs. >3 positive nodes was considered (not shown).
The mean tumour diameter was greater in VIM + ve
carcinomas (2.9+0.48cm vs. 2.2+0.12cm, P<0.03) and in
EGF-R + ve ones (2.6+0.32 cm vs. 2.1+0.1 cm; P =0.06).
p53 and VIM +ve infiltrating duct carcinomas were more
frequently scored as grade III (14/20 p53 +ve vs. 24/74 p53
-ve, X2=9.24, df 2, P=0.01; 16/26 VIM +ve vs. 25/73
VIM -ve, x2=4.81, df 1, P<0.03).
Discussion
In this report we show that three unrelated cell proteins
(nuclear p53, cytoplasmic vimentin and membrane EGF-R)
cluster together and are expressed on hormonally defined
subgroups of breast carcinomas.
Apart from the well-regulated distribution of vimentin in
normal tissues and their malignant counterparts (reviewed by
Gould, 1985), the de novo expression of this IF, together
with other constitutive cytoskeletal proteins, has been the
subject of extensive analysis. Two papers describe vimentin
in breast carcinomas: one shows its presence in single cells in
body fluids (Ramaekers et al., 1983) and another, in a subset
of breast and non-breast carcinomas (Azumi & Battifora,
1987). The coexpression of keratin and vimentin IF in
epithelial malignancies has been associated with alterations is
the shape and motility of the transformed cells (Henzen-
Logmans et al., 1987).
The de novo expression of vimentin during in vitro culture
of epithelial cells has been shown to be a function of culture
conditions (Ben-Ze'Ev, 1985; Rheinwald et al., 1986) and the
nutrients supplemented, with special reference to the
hormones (hydrocortisone, insulin and prolactin) added to
the media (Schmid et al., 1983). Cells grown in hormone-
depleted sera expressed vimentin IF whereas they did not
when supplemented culture medium was added (Schmid et
al., 1983). It is not therefore unexpected to find the
Table I Expression of vimentin, p53 and EGF-R on ER-ICA positive and negative breast
cancer
Total cases (%) ER-ICA -ve (%) ER-ICA + ve (%) x2 p
Vimentin 49/196 (25) 26/45 (57.8) 23/151 (15.2) 31.23 <0.001
p53 31/196 (15.8) 23/45 (51.1) 8/151 (5.3) 51.26 <0.0001
EGF-R 67/196 (34.2) 27/45 (60) 40/151 (26.5) 15.84 <0.001VIMENTIN, p53 AND EGF-R EXPRESSION IN BREAST CANCER 355
Figure 1 (a) PAb421-positive breast cancer. Nuclear positivity is present on tumour cells but not on stromal cells (arrows).
APAAP staining on frozen section ( x 600); (b) Vimentin-positive breast cancer. Tumour cells are labelled (arrows). ABC staining
on formalin-fixed, paraffin-embedded specimen (x 320); (c) EGF-R positive breast cancer. Membrane positivity is shown on
tumour but not on stromal cells. APAAP staining on frozen section ( x 270). Scale bar= 5pm.
Figure 2 (a) Vimentin-positive breast cancer. Anti-cytokeratin
antibody UCD/PR 10.11 selectively stains the epithelial cells, but
not the stroma. TRITC immunofluorescence (x 500); (b)
Vimentin positive breast cancer. Polyclonal anti-vimentin
antibody stains both the stroma and the tumour cells (asterisks).
The staining pattern of vimentin on epithelial cells partially
overlaps the cytokeratin staining but is more intense around the
nucleus. FITC immunofluorescence. Same field as in (a) ( x 500).
Scale bar=5gm.
phenotypic traits of an exogenously hormone-deprived cell in
a tumour that lacks the appropriate hormone receptor.
Experimental evidence that VIM is selectively expressed in
hormone-independent, oncogene-transformed epithelial cell
lines has been recently reported (Agnor et al., 1987).
The vimentin gene was cloned from serum stimulated
hamster fibroblasts (Rittling et al., 1986) and expression was
shown to be regulated at the transcriptional level be serum-
Figure 3 Double immunoenzymatic stain for ER-ICA (brown
nuclei in the original colour slide) and for vimentin (blue
cytoplasmic stain in the original colour slide). Double stained
tumour cells are shown (arrows). Note the weak nuclear ER-ICA
staining, typical of vimentin-positive breast carcinomas.
Vimentin-positive stromal cells and lymphocytes (double arrows)
do not show nuclear ER-ICA staining ( x 625). Scale bar-= pm.
derived growth factors such as PDGF, but not EGF, insulin
or platelet-poor plasma (Ferrari et al., 1986). Vimentin and
the myc gene are induced with similar kinetics in early G1
phase (Rittling et al., 1986).
p53, which has been included on the nuclear oncogene
family because of its biological transforming activity
(Eliyahu et al., 1984), bears no homology with known proto-
oncogenes; however, it resembles another gene (myc) as far
as its transforming strength, subcellular location and
activation kinetics in in vitro models are concerned (Bienz et
al., 1984). By contrast with myc and vimentin, the p53 gene
is maximally expressed in the mid G1 cell cycle phase
(Rittling et al., 1986). p53 may be a regulatory element for
the induction or maintenance of replicative DNA synthesis
(Braithwaite et al., 1987; Mercer et al., 1982).
p53 is readily expressed after mitogen stimulation of
normal cells in vitro (Mercer & Baserga, 1985), but not on
resting cells, nor was it detectable on various normal tissues,
including breast and mammary dysplasia (Cattoretti et al.,
1988). The presence of EGF-R has already been shown to be
associated with large, high-grade, ER -ve breast carcinomas
(Sainsbury et al., 1987). EGF-R is at the same time the
receptor for a natural mitogen on epithelial cells (Taketani &
Oka, 1983) and the cellular homologue of the viral oncogene
erb-B (Downward et al., 1984).356 G. CATTORETTI et al.
Table II Subsets of breast carcinomas defined by the combination
of vimentin, p53, EGF-R and ER-ICA reactivity
ER-ICA ER-ICA
VIM p53 EGF-R -ve + ve Total
+ - - 2 12 14
- + 4 3 7
_ - + 4 26 30
+ + - 3 3
+ - + 7 9 16
- + + 2 3 5
+ + + 14 2 16
Subtotal 36 55 91
9 96 105
Total 45 151 196
Table III Expression of vimentin and EGF-R on p53 negative
breast cancer subsets
Vimentin
+ ve (%) EGF-R + ve (%)
Total 30/164 (18.3) 46/164 (28)
ER-ICA -ve 9/22 (40.9) 11/22 (50)
ER-ICA +ve <50%a 11/49 (22.4) 18/49 (36.7)
ER-ICA +ve >50%a 10/93 (10.8) 17/93 (18.3)
X2 11.63 11.48
P value <0.003 <0.003
aPercentage of tumour cells stained.




Vimentin +ve 81.56+26.54 t= 1.32, df 130, P=0.18 Vimentin -yve 127.15+18.51 t=32dlOP08
p53 +ve 27.82+ 7.96 t=2.43, df 130, P<0.05
EGR-R -ve 136.10+21.13 t= 1.92, df 130, P=0.053
PgR values +s.e.
(fmolmg-1 protein) Significance
Vimentin +ve 139.17 +45.04 t=1.41,dfl30,P=0.15
Vimentin -yve 225.34+33.1
p53 +ve 67.2+25.18 t =2.12, df 130, P=0.03
p53 -yve 225.88+31.2 t2.2dlOP03
EGF-R +ve 107.89+24.9 t=258dr10P= .I EGF-R -ve 252.09+38.55 t=2.58, dr 130, P=0.01
Several pieces of experimental evidence indicate that the
inverse relationship found between ER on the one hand and
p53, VIM and EGF-R on the other, has some basis in the
proliferative status of the tumour cell; breast cancer
progenitor cells in culture lack ER (Kodama et al., 1985)
and rapidly proliferating cells accumulate a low amount of
the receptor (Jakesz et al., 1984). p 53 itself has been found
to parallel the RNA content of cycling cells and the p53
intracellular content rises when the cell proceeds to the
Glb-G2 phase (Darzynkiewicz et al., 1986). p53 +ve
carcinomas display significantly higher reactivity with the
proliferation associated Ki-67 MAb and express a higher
amount of the transferrin receptor (Cattoretti et al., 1988).
Similarly, the median percentage of S-phase cells is higher in
tumours lacking both ER and PgR (McGuire et al., 1986;
McGuire & Dressler, 1985).
In addition, the presence of EGF-R may indicate the
ability of the cell to be stimulated by natural mitogens such
as EGF or TGFa, the latter also being able to partially
replace the tumour promoting effect of oestrogen (Dickson
et al., 1986). The presence of EGF-R immunoreactivity has
also been positively related to a high S-phase content of
breast cancer (Walker & Camplejohn, 1986). We can thus
speculate that the presence of either one of p53, VIM or
EGF-R is an indicator of an actively cycling tumour cell
with a reduced amount of ER or a diminished requirement
of ER to grow.
Approximately half of the breast cancer specimens found
positive for one marker were positive for another one or
two, but all the possible combinations were represented as
outlined in Table II. The large spectrum of phenotypes
observed can be explained in two ways: either minimal
amounts of the apparently negative cell marker could not be
detected in some cases because of the limited sensitivity of
the technique employed; or because the genes involved
depend on coincident, but not identical, stimuli to be
expressed and therefore the membrane phenotype is indeed
heterogeneous. Although we are aware of the limitations of
the very sensitive techniques we used, ~ye favour the latter
explanation. There is experimental evidence that myc and
p53 respond differently to EGF (Filmus et al, 1987),
phytohemagglutinin and interleukin 2 (IL2) stimulation
(Reed et al., 1986). However, both are expressed in cycling
cells together with the IL2 receptor and both are necessary
for IL2-induced growth (Reed et al., 1986). Vimentin, in
contrast to myc, responds to PDGF but not to EGF.
There is also evidence that a tumour cell with a given
growth factor receptor repertoire may produce multiple
growth factors, even those for which it has no membrane
receptors (Betsholtz et al., 1987); furthermore, not all
tumour cell lines produce the same variety of growth factors
(Peres et al., 1987).
If we assume that p53 and vimentin depend on two
separate combinations of growth factors and receptors to be
induced, then it is conceivable that coexpression of both in
tumour cells reflects the frequent but not obligate coexistence
of several autocrine pathways.
Despite all the caveats outlined above, we identified two
well characterized proteins which definitely indicate the
cellular phenotype of an ER negative breast carcinoma and
thus may facilitate the search for the appropriate growth
factors and receptors.
Whether the combined expression of EGF-R, vimentin
and p53 contributes a growth advantage to the tumour
causing a more aggressive, hormone-independent prolifer-
ation of a given carcinoma must still be determined by in
vitro and ad hoc clinical studies.
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